IMPACT OF POLYPHARMACY ON THE EFFICACY AND SAFETY OF SGLT2 INHIBITORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/05e9b0d1eb874c720b1e8c09ce460818.pdf
IMPACT OF POLYPHARMACY ON THE EFFICACY AND SAFETY OF SGLT2 INHIBITORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Emily
Yeung
Emily Yeung eyeung@georgeinstitute.org.au The George Institute for Global Health Renal and Metabolic Division Sydney Australia *
Amanda Siriwardana asiriwardana@georgeinstitute.org.au The George Institute for Global Health Renal and Metabolic Division Sydney Australia -
Luke Buizen lbuizen@georgeinstitute.org The George Institute for Global Health Renal and Metabolic Division Sydney Australia -
Arthur Tang atang@georgeinstitute.org.au University of Hong Kong Department of Renal Medicine Hong Kong Hong Kong, China -
Lauren Heath lauren.heath91@gmail.com The George Institute for Global Health Renal and Metabolic Division Sydney Australia -
Min Jun mjun@georgeinstitute.org.au The George Institute for Global Health Renal and Metabolic Division Sydney Australia -
Sydney Tang scwtang@hku.hk University of Hong Kong Department of Renal Medicine Hong Kong Hong Kong, China -
Sradha Kotwal skotwal@georgeinstitute.org.au The George Institute for Global Health Renal and Metabolic Division Sydney Australia -
Clare Arnott carnott@georgeinstitute.org.au The George Institute for Global Health Cardiovascular Division Sydney Australia -
Adeera Levin alevin@providencehealth.bc.ca The University of British Columbia Department of Nephrology Vancouver Canada -
Meg Jardine meg.jardine@sydney.edu.au University of Sydney NHMRC Clinical Trials Centre Sydney Australia -
Kenneth Mahaffey kmahaf@stanford.edu Stanford University School of Medicine Stanford Center for Clinical Research Palo Alto United States -
Vlado Perkovic vlado.perkovic@unsw.edu.au University of New South Wales Faculty of Medicine Sydney Australia -
Hiddo Heerspink h.j.lambers.heerspink@umcg.nl University of Groningen Clinical Pharmacy and Pharmacology Groningen Netherlands -
Brendon Neuen bneuen@georgeinstitute.org.au The George Institute for Global Health Renal and Metabolic Division Sydney Australia -